If you decide to discontinue TKI after prolonged molecular remission in CML, how often would you follow the BCR/ABL after discontinuation?
Answer from: Medical Oncologist at Academic Institution
The NCCN has updated the guidelines and included specific and detailed criteria for TKI discontinuation. Per the NCCN guidelines: "Monthly molecular monitoring for one year, then every 6 weeks for the second year, and every 12 weeks thereafter (indefinitely) is recommended for patients who remain in...
Sign in or Register to read more